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ABSTRACT 
Glioblastoma Multiforme is one of the 
most aggressive form of malignancy of 
the central nervous system. To date, the 
treatment of this malignancy does not 
significantly improve the poor overall 
survival of the patients. The dramatic 
outcomes of immunotherapy in the 
treatment of several solid and 
hematologic tumors are giving new hopes 
for the treatment of glioblastoma. A series 
of clinical studies are currently ongoing, 
encouraged by the promising pre-clinica l 
results achieved. PD-L1 is one of the 
main immunotherapy molecular targets 
expressed on glioma cell surface. PD-L1 
interacts with the cognate receptor PD1, 
expressed on the lymphocytes, and 
conveys an immune- inhibitory signalling. 
Increasing evidence suggests that PD-L1, 
in addition to its well-known 
immunomodulatory function, exerts 
tumor intrinsic functions that sustain self-
renewal and growth. Currently, the 
overall mechanism that regulates the 
expression of PD-L1 in tumor cells is still 
unclear. Glioma tumors express high 
levels of the immunophilin and co-
chaperone FKBP51. Our research group 
have identified a splicing isoform of this 
immunophilin, FKBP51s, in melanoma 
patients and provided elements in support 
of a role for this isoform as a foldase that 
serves to PD-L1 protein maturation. The 
aim of my thesis work was to address the 
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role of FKBP51s in regulation of PD-L1 
expression in glioblastoma. Moreover, I 
also attempted to investigate whether PD-
L1 could affect the tumor intrinsic pro-
oncogenic properties.  
To analyse the role of FKBP51s on PD-
L1 expression and function, I used D54 
and U251 glioblastoma cell lines that 
constitutively express PD-L1 and 
FKBP51s. By immunoblot and flow 
cytometry, I measured the expression of 
FKBP51s and PD-L1. By sub-cellula r 
fractionation and co-
immunoprecipitation assays, I 
investigated FKBP51s localization and 
interaction with PD-L1. By co-cultures 
with PBMCs, I measured the tumor 
capacity to kill lymphocytes through PD-
L1. By spheroids assay, 
immunofluorescence for Ki67 and cell 
counting, I measured the effect of PD-L1 
and FKBP51s on glioma cell self-renewal 
and growth capacities. Using a murine 
model of glioblastoma, made by injection 
of GFP+luc+ U87 cells, I addressed the 
effect of a selective inhibitor of FKBP51, 
called SAFit2, on tumor growth and 
aggressiveness.   
Results obtained showed that FKBP51s is 
abundantly expressed in glioma cells. 
FKBP51s co-localized with PD-L1 in the 
ER. Silencing of FKBP51s expression or 
inhibiting its function by SAFit2 
decreased glycosylated PD-L1 levels and 
its expression on plasma membrane. 
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Moreover, PD-L1 silencing decreased 
spheroids formation especially in a subset 
of tumor cells which is isolated by the 
subventricular zone (SVZ) and has a high 
tumorigenic capacity. The same effect 
was obtained with SAFit2 that also 
decreased Ki67 expression and 
proliferation capacity of glioblastoma 
cells. Daily treatment with SAFit2 
reduced the volumes of formed tumors, in 
the in vivo glioblastoma model, and 
reduced the vimentin expression, in 
comparison with tumors from mice 
treated with the drug vehicle. 
In conclusion, FKBP51s is involved in a 
post-transcriptional mechanism that 
regulates PD-L1 maturation and 
consequent expression on glioblastoma 
plasma membrane. Glioblastoma cells 
with a high tumorigenic capacity, 
identified in the SVZ, expressed higher 
levels of PD-L1 compared with cells from 
the tumor mass grown in the nigrostriata l 
region. Inhibiting FKBP51s function 
decreases PD-L1 expression and reduces 
self-renewal and growth capacities of 
glioblastoma cells in vitro and in vivo. 
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1. INTRODUCTION 
 
Glioblastoma 
 
Glioblastoma Multiforme is the most 
common and aggressive form of 
malignancy of the central nervous system 
(Louis et al. 2007). According to World 
Health Organization (WHO) 
Classification System, which refers to 
histological and immunohistochemica l 
analogies to presumed origin cells and 
histological features of aggressiveness 
(Luois et al. 2016), glioblastoma 
multiforme is classified as IV grade 
glioma, the higher grade of severity. The 
current clinical course for glioblastoma 
treatment, that consists in maximal 
surgical resection followed by 
radiotherapy and treatment with 
temozolomide (Weller et al. 2014), does 
still not represent a valid tool to fight this 
malignancy and today the overall median 
survival hardly reaches the 15 months 
after diagnosis (Furnari et al. 2007). High 
frequency of tumor recurrence is the 
cause for the poor median overall 
survival. Currently, we know that 
recurrence is mostly related to the 
presence of self-renewing cells called 
GBM- initiating cells (GICs), able to 
escape conventional treatments and 
regenerate the tumor (Liu et al. 2011). 
GICs, as in general the “Cancer Initiat ing 
Cells”, are considered a fraction of the 
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tumor cells that retain self-renewal and 
differentiation abilities, with a high 
tumorigenesis potential in vivo 
experimental models (Weissman et al. 
2001). Because GICs have shown 
abilities that are shared with neural stem 
cells (NSC), it is still unclear whether 
glioma cells come from NSCs or 
differentiated cells, as astrocytes or 
oligodendrocytes (Goffart et al. 2013). 
Recent studies by Kroonen et al. have 
demonstrated that GICs have a specific 
tropism for the sub-ventricular zones 
(SVZ) (Kroonen et al. 2011). Moreover, 
cells from SVZ showed a higher 
resistance to treatment with ionizing 
radiations compared with the tumor mass 
cells (Goffart et al. 2017). SVZ represents 
one of the most important neurogenic 
niches in adult brains, sustaining self-
renewal and inhibiting differentiat ion 
(Alvarez-Buylla et al. 2002). Probably 
due to these characteristics, in the SVZ, 
GICs find a “fertile soil” for tumor 
reformation. 
If GICs are also generated from adult 
neural stem cells (NSC) residents in the 
SVZ is still a controversial topic. A series 
of studies have demonstrated that the 
induction of cancerous transformation in 
NSC cells, by tumor suppressor genes 
inactivation as p53 and neurofibromatos is 
1 (NF1) or the expression of a mutant 
form of p53, triggered glioma formation 
and the localization of the tumors formed 
showed to be associated with the SVZ 
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(Wang et al. 2009; Zhu et al. 2005; 
Alcantara Llaguno et al. 2009). On the 
other hand, further studies have 
demonstrated that also NSC-derived 
progeny cells, as oligodendrocytes and 
astrocytes precursor cells, could undergo 
a cancerous transformation (Bachoo et al. 
2002, Lindberg et al. 2009, Persson et al. 
2010)      
In the last years, a deeper understand ing 
of the common genetic lesions that 
characterize GBM, highlighted several 
molecular factors that might drive the 
high aggressiveness of this tumor. 
Epidermal Growth Factor Receptor 
(EGFR) has shown to be amplified in 40 
to 50% of GBMs (Cancer Genome Atlas 
Research 2008). A series of gain-of-
function mutations sustain the 
amplification of EGFR signalling, the 
most common of which is deletion of 
exons 2-7 that encode the ligand binding 
domain of the receptor, generating the 
constitutively active “EGFR variant III” 
(EGFRvIII) (Huang et al. 2009). EGFR 
amplification is frequently accompanied 
by the Phosphatase and tensin homolog 
(PTEN) loss of function resulting in a 
strong activation of phosphatidylinosito l-
4,5-bisphosphate 3-kinase (PI3K) 
signalling (Huang et al. 2009). Genetic 
lesions that activate PI3K pathway occur 
in 90% of GBMs (Cancer Genome Atlas 
Research 2008), thus it is not surprising 
that together with EGFR inhibitors, as 
Erlotinib and Gefitinib, PI3K and Protein 
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Kinase B (AKT) inhibitors have been 
considered as promising tools for GBM 
treatment. However, clinical studies have 
demonstrated that the tumor easily gains 
resistance to these drugs (Cloughesy et al. 
2014). Mammalian target of rapamycin 
(mTOR) represents another compelling 
target in GBM treatment: the kinase 
exists as two distinct complexes, called 
mTOR complexes I and II (mTORC1 and 
mTORC2), which are characterized by a 
different function, regulation and 
response to the allosteric inhibito r 
rapamycin (Cloughesy et al. 2014). 
mTORC1 integrates growth factor 
receptor signalling via PI3K, with 
downstream promotion of cell 
proliferation, protein translation and 
inhibition of autophagy, to promote GBM 
growth and survival (Laplante and 
Sabatini 2012). Conversely, mTORC2 
promotes GBM growth and surviva l 
through activation of nuclear factor 
kappa-light-chain-enhancer of activated 
B cells (NF-κB) (Tanaka et al. 2011). 
Alterations of PI3K signalling and PTEN 
loss are both involved in constitut ive 
activation of mTORC1 and mTORC2 in 
GBM (Cloughesy et al. 2014). 
Unfortunately, once a time, Phase I and 
Phase II clinical studies on GBM patients 
have shown that rapamycin did not 
produce the promising benefits due to 
cancer resistance (Tanaka et al. 2011).  
The Cancer Genome Atlas database, that 
had successfully established a 
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comprehensive catalogue of genomic 
alterations in a large cohort of GBM 
patients, has given the opportunity to 
generate a classification of GBM into 
four subtypes denoted mesenchymal, 
proneural, classical and neural (Verhaak 
et al. 2010). Mesenchymal subtype is 
characterized by low expression of NF1, 
partly due to hemizygous deletions of the 
region containing the gene that 
predominantly occurred in this subtype 
(Verhaak et al. 2010). As suggested by 
the subtype name, Mesenchymal subtype 
is characterized by the expression of a 
series of mesenchymal markers such as 
CHI3L1 and MET (Phillips et al. 2006). 
Genes of the tumor necrosis factor 
superfamily and NF-κB pathway are 
highly expressed in this subtype (Verhaak 
et al. 2010). Characteristic of the 
Proneural subtype is the high expression 
of several proneural development genes 
such as SOX genes (Phillips et al. 2006). 
Another signature of this subtype is the 
high expression of oligodendrocytic 
development genes such as PDGFRA, 
NKX2-2 and OLIG2 (Noble et al. 2004). 
High expression of PDGFRA is mostly 
related to an amplification of the locus 
harbouring the gene (Verhaak et al. 
2010).  A work by Ligon et al. has shown 
that the high expression of OLIG2 
promoted proliferation by 
downregulation of the tumor suppressor 
p21 (CDKN1A) (Ligon et al. 2007).  
EGFR amplification characterized the 
Classical subtype, frequently 
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accompanied by point or vIII EGFR 
mutation (Verhaak et al. 2010). This 
subtype is also distinguished for a lack of 
TP53 mutations (Verhaak et al. 2010). 
The Neural subtype is characterized by 
the presence of neural markers such as 
GABRA1, SYT1 and NEFL (Verhaak et 
al. 2010)        
So far, notwithstanding progress in the 
knowledge of the biology of this tumor, 
the treatment  still remains a challenge for 
clinicians and the prognosis for GBM 
remains bad. Recent developments in the 
immunotherapy of cancer, with 
monoclonal antibodies that target the so-
called “immune checkpoints inhibitors”, 
have opened the door to new hopes for 
GBM cure. 
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The immune checkpoint programmed 
cell death ligand-1 (PD-L1) 
 
Current developments in cancer treatment 
are emphasizing the role of the immune 
system in controlling tumor formation. 
Glioblastoma has long been recognized 
as a tumor able to create an 
immunosuppressive milieu through 
different mechanisms (Preusser et al. 
2015; Tran et al. 2007; Wainwright et al. 
2014; Berghoff et al. 2015; Huang et al. 
2017). Inhibition of TGF  signaling 
improved the overall survival in a mice 
model of glioblastoma, not only by 
inhibiting the tumor cell migration ability 
mediated by the cytokine, but also 
stimulating the immune system attack to 
the tumor (Tran et al. 2011). Indoleamine 
2,3 dioxygenase (IDO) has shown to be 
another important immunosuppress ive 
factor for glioblastoma development: in a 
mice model, glioma cells negative for 
IDO expression, have a reduced capacity 
to form the tumor comparing to IDO-
competent cells (Wainwright et al. 2014). 
Stimulation of the cancer surveillance 
function of the immune system, by 
targeting the immune checkpoint 
inhibitors, has demonstrated to be 
effective in inducing a durable remiss ion 
in a number of tumors (Yao et al. 2013). 
The immune checkpoint inhibitors 
generally rely on several couples of 
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receptor/counter-receptor, the cognate 
interactions of which activate an 
immunosuppressive pathway which 
dampens the antigen-induced T cell 
activation. One of these interactions 
involves  Programmed Cell Death-1 
(PD1), expressed on T-lymphocytes 
surface, and Programmed Cell Death 
Ligand-1 (PD-L1), the cognate ligand. 
PD-L1 and its closest homologue PD-L2 
are B7 family members. PD-L1 has broad 
tissue distribution, including both 
lymphoid and non-lymphoid organs, and 
it is also inducible in response to pro-
inflammatory cytokines (Yao et al. 2013). 
By contrast, the expression of PD-L2 is 
mainly restricted to DCs and 
macrophages. The physiological function 
of the PD-L1/PD1 axis is in the control of 
human T cell activation and maintaining 
self-tolerance (Yao et al. 2013).  
Most of the immune checkpoints that act 
on the plasma membrane contain one or 
more immunoglobulin (Ig) domains, 
involved in the interaction with the 
cognate receptors and in the signa l 
transduction to intracellular domains 
(Reviewed in Krzysztof et al. 2017). PD-
L1 structure is composed of two Ig-like 
domains: the Ig-like domain of the N-
terminal is responsible for binding PD-1, 
while is still unknown the function of the 
second Ig-like domain in the C-termina l 
(Reviewed in Krzysztof et al. 2017). 
Interestingly, in all available crystal 
structures PD-L1, has shown to be able to 
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form homodimers, but no experimenta l 
cell data are available about such ability 
(Reviewed in Krzysztof et al. 2017).         
PD-L1 is sometimes aberrantly expressed 
by tumor cells. The triggering of 
PD1/PD-L1 pathway inhibits T-cell 
activation and proliferation by recruit ing 
SHP-1 and SHP-2 phosphatases to TCR 
which (Parry et al. 2005) weakens the 
signal. Moreover, PD1/PD-L1 interact ion 
induces the up-regulation of the 
transcription factor ATF-like (BATF), 
which impairs cell proliferation and 
cytokine secretion (Quigley et al. 2010). 
Another effect of PD1 triggering is the 
inhibition of the pathways downstream to 
PI3K and activated-extracellular-
regulated kinase (ERK) which also affect 
cell cycle progression and proliferation of 
T-cells (Patsoukis et al. 2012). 
Interestingly, in addition to its 
immunomodulatory function, a role for 
PD-L1 in sustaining tumor features of 
aggressiveness and stemness has been 
also proposed, raising the hypothesis of a 
possible involvement of PD-L1/PD1 
pathway in conveying a survival signal to 
the tumor. A study by Zheng et al. shows 
that treatment with anti-PD-L1 is able to 
impair growth rate and ability to form 
spheres in melanoma cell lines. 
Collectively, the research group 
demonstrated that PD-L1 plays an 
important role in sustaining the self-
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renewal of malignant melanoma-
initiating cells (Zheng et al. 2017).   
PD-L1 is highly expressed in 
glioblastoma specimens from patients 
(Berghoff et al. 2015; Nduom et al. 2016) 
and its expression showed to be higher 
compared to other tumors as melanoma 
and non-small cell lung cancer (NSCLC) 
(Huang et al. 2017). In a preclinical study 
on GL261 glioma mouse model, 
treatment with anti-PD1 antibodies in 
combination with radiotherapy increased 
the percentage of long-term surviva l 
compared with mice treated with 
radiotherapy only (Zeng et al. 2013). 
Encouraged by these pre-clinical results, 
currently, a series of clinical studies 
involving GBM patients are ongoing. A 
clinical study is testing the tolerability 
and efficacy of the anti-PD1 monoclona l 
antibody Nivolumab, alone or in 
combination with Ipilimumab, an anti-
CTLA4 monoclonal antibody, in 
comparison to the effect of Bevacizumab, 
in recurrent GBM patients 
[NCT02017717]. Other two studies, on 
recurrent GBM patients, are testing the 
efficacy of Pembrolizumab, (which 
targets PD1) in combination with 
Ipilimumab [NCT02337491] or with 
Magnetic Resonance Imaging (MRI)-
guided laser ablation [NCT02311582]. 
Moreover, a fully human monoclona l 
antibody against PD1, called 
Durvalumab, is being tested in GBM 
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patients in combination with radiotherapy 
and bevacizumab [NCT02336165].     
Ionizing radiation has shown to up-
regulate PD-L1 expression (Song et al. 
2018). Song et al. have demonstrated that 
radiotherapy increases mRNA and 
protein levels of PD-L1 in U87 and U251 
glioma cell lines, moreover, the research 
group demonstrated that the mechanism 
of up-regulation was dependent on the 
EGFR pathway (Song et al. 2016). 
In agreement with Benavente et al. 
(Concha-Benavente et al. 2016), PD-L1 
expression in tumor cells is regulated by 
two major mechanisms. One mechanism 
is related to the production of pro-
inflammatory cytokines, in particula r, 
IFN- produced by natural killer (NK) 
cells and CD8+ Cytotoxic T lymphocytes 
(CTLs). The second mechanism, 
considered as a more “intrins ic” 
mechanism independent of IFN- activity 
involves EGFR/JAK2 pathways in 
sustaining tumor cell PD-L1 expression.        
In addition to the transcriptional control, 
a number of studies have described a 
complex and sophisticated mechanism of 
post-transcriptional control of PD-L1 
expression. Parsa et al. showed that AKT 
pathway can trigger PD-L1 expression in 
glioma cells through a translationa l 
mechanism, involving the assembly of 
polyribosomes complex that increases the 
protein levels without affecting the 
mRNA levels (Parsa et al. 2007). Burr et 
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al. described a mechanism that involved 
PD-L1 recycling on plasma membrane : 
their study demonstrated that CMTM6, 
involved in protein recycling, interacts 
with PD-L1 and inhibits the protein 
degradation mediated by endosome 
vesicles and thus promotes PD-L1 
permanency on plasma membrane (Burr 
et al. 2017). Another mechanism, 
proposed by Chia-Wei et al., points to 
PD-L1 glycosylation as a further element 
that influences protein stability: this 
model suggests that non-glycosylated 
PD-L1 interacts with GSK3 and is 
conveyed to the proteasome via 
ubiquitination (Li et al. 2016). Most 
recently, a further element has been 
identified as involved in post-
translational control of PD-L1 
expression, namely the short isoform of 
the FK506 binding protein 51 (FKBP51s) 
which served as co-chaperone in protein 
glycosylation (Romano, D’Angelillo, 
Staibano et al. 2015). 
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FK506 binding protein 51 (FKBP51) 
 
FKBP51 is a member of the 
immunophilin family, a large group of 
proteins characterized for their isomerase 
function, which catalyse the conversion 
between cis and trans isomers of a 
peptide bond containing the amino acid 
proline (reviewed in D’Arrigo et al. 
2016). Members of this family were 
originally identified as receptors for 
immunosuppressive drugs, thus, the 
“FKBP” group were first characterized as 
FK506, also known as Tacrolimus, 
Binding Proteins (reviewed in D’Arrigo 
et al. 2016). FKBP51 was firstly cloned 
in lymphocytes and identified as an 
important modulator of FK506 
immunosuppressive function: the protein 
showed to inhibit Calcineur in 
phosphatase when complexed with 
FK506, thus impairing lymphocyte 
activation (Baughman et al 1995). The 
structure of the protein consists of three 
C-terminal “TPR” domains, responsible 
for the interaction of FKBP51 with other 
proteins, in particular Hsp90 and Hsp70; 
conversely the N-terminal contains two 
FKBP domains, FK1 and FK2, among 
which the FK1 domain exerts the 
isomerase activity of the protein 
(Romano, Sorrentino et al. 2011).    
In addition to its function in lymphocytes, 
FKBP51 was found abundantly expressed 
in several tumors (reviewed in Romano, 
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D’Angelillo and Romano 2015) includ ing 
glioblastoma (Jiang et al. 2008). A study 
of specimens from 192 patients, includ ing 
glioblastoma multiforme, 
oligodendrogliomas, astrocytomas, and 
mixed gliomas, showed that FKBP51 
expression level correlated with grading 
and overall glioblastoma patient surviva l 
rates; that is, the glioblastoma patients 
with high levels of FKBP51 had shorter 
survival than those with intermediate 
levels (Jiang et al. 2008).  
Several studies in tumor cell lines have 
delineated the role of FKBP51 especially 
in sustaining cell proliferation and 
chemoresistance to conventional anti-
cancer therapies (reviewed in Romano, 
D’Angelillo and Romano 2015): the 
protein sustains tumoral growth 
essentially by promoting NF-κB 
activation (Romano, Mallardo et al. 
2011) and steroid receptor functions (Ni 
et al. 2010). In glioblastoma cell lines, 
Jiang et al. have demonstrated that 
FKBP51 promoted cell growth by 
activating NF-κB and moreover, 
silencing of FKBP51 increased 
rapamycin effect on glioma growth (Jiang 
et al. 2008). 
Our research group has previous ly 
characterized the role of FKBP51 in 
melanoma biology and progression. 
Inhibition of FKBP51 by RNA silenc ing 
or treatment with rapamycin increased 
melanoma sensitivity to the pro-apoptotic 
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effect of doxorubicin (Romano et al. 
2004); the protein activated the pro-
survival signaling of NF-κB by 
interacting with IKK complex and 
promoting its activity (Romano, Xiao et 
al. 2015). Moreover, the activity of 
FKBP51 on NF-κB signaling also 
modulated melanoma sensitivity to 
ionizing radiations (Romano et al. 2010). 
It is to be noted that, rapamycin or FK506 
target the activity of structurally simila r 
proteins that sometimes exert even 
opposite functions as FKBP51 and 
FKBP52 (Gaali et al. 2015). Recently, 
highly selective inhibitors of FKB51 have 
been created and named SAFit1 and 
SAFit2, for Selective Antagonist by 
Induced Fit. The chemical agents 
“induce” a conformational change to 
selectively “fit” to the protein target 
(Gaali et al. 2015). The research group of 
professor Felix Hausch, who designed the 
molecules, demonstrated that SAFits 
enhanced neurite outgrowth in neuronal 
cell lines (Gaali et al. 2015). More 
recently, a work by our research group 
highlighted a further crucial effect of 
SAFits on melanoma cell lines (Romano, 
Xiao et al. 2015). Treating melanoma cell 
lines with SAFits strongly impaired 
FKBP51 control on IκBα degradation and 
decreased NF-κB activation and cyclin 
D1 transcription (Romano, Xiao et al. 
2015). 
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Recently, a spliced variant of FKBP51, 
termed FKBP51s, has been identified for 
the first time by our research group in 
peripheral blood of melanoma patients. 
FKBP51s differs from the canonica l 
isoform because of lacking the TPR 
domains and having a distinct C-termina l 
domain (Romano, D’Angelillo, Staibano 
et al. 2015). Such a splicing variant was 
induced following tumor interaction with 
immune cells through PD-L1/PD1 and 
appeared to be involved in the regulat ion 
of PD-L1 expression (Romano, 
D’Angelillo, Staibano et al. 2015).    
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Identification of FKBP51s as a PD-L1 
regulator 
 
Romano et al demonstrated that 
engagement of PD-L1 with its receptor 
PD1 bidirectionally induces a spliced 
isoform of FKBP51 in both melanoma 
cell and the lymphocyte (Romano, 
D’Angelillo, Staibano et al. 2015). Such 
a splicing was accompanied by 
upregulation of PD-L1 expression 
(Romano, D’Angelillo, Staibano et al. 
2015). FKBP51s was found to physically 
interact with PD-L1. This finding, 
together with the observation that 
FKBP51s affected especially the level of 
glycosylated PD-L1 and in line with the 
protein isomerase function, suggesting a 
role for FKBP51s in post-translationa l 
regulation of PD-L1 expression, as a 
foldase (Romano, D’Angelillo, Staibano 
et al. 2015). An immunohistochemistry 
study of 76 melanoma tissues from 
patients showed a positive correlation 
between melanoma PD-L1 expression 
and FKBP51s expression in TILs 
(Romano, D’Angelillo, Staibano et al. 
2015). Increased expression levels of 
FKBP51s, was also measured by qPCR in 
PBMCs of a study population that 
included 99 primary and 25 metastatic 
melanoma patients (Romano, 
D’Angelillo, Staibano et al. 2015). Very 
recently, expression of FKBP51s has 
been investigated also in PBMC subsets 
from 118 advanced melanoma patients 
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and 77 normal donors, showing that CD4, 
CD8 and CD25 T lymphocytes subsets 
contained a proportion of an FKBP51spos 
component, that resulted significantly 
increased in melanoma patients and 
associated with reduced overall surviva l 
(Romano et al. 2017). This study 
suggested that FKBP51s expression in 
TILs and PBMCs was associated with a 
condition of tumor-induced immune 
suppression, with a negative impact on 
melanoma prognosis (Romano et al. 
2017). Taken together, our previous 
studies provide elements in support of a 
melanoma/host immune system 
interaction that activates the splicing of 
FKBP5, which concurs to melanoma 
immune evasion by upregulation of PD-
L1 (Romano, D’Angelillo, Staibano et al. 
2015) and T lymphocyte impairment 
(Romano et al. 2017).  
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2. AIM 
 
Because glioma contains high levels of 
FKBP51 (Jiang et al. 2008) and PD-L1 
(Berghoff et al. 2015; Nduom 2016; 
Huang et al. 2017), it appeared to be an 
optimal model for addressing the role of 
the recently identified FKBP51s in PD-
L1 expression regulation. Furthermore, 
the efficacy of selective FKBP51 
inhibitors on PD-L1 expression and GBM 
oncogenic features was also investigated.  
The aims of my PhD project are: 
 Study of expression of FKBP51s and 
PD-L1 in glioblastoma cell lines and 
glioma sections from patients 
 Study of FKBP51s regulation of PD-L1 
glycosylation  
 In vitro studies of the effects of small 
molecules selective inhibitors of 
FKBP51 on PD-L1, both constitutive ly 
expressed and induced by ionizing 
radiations 
 Study of PD-L1 involvement in tumor 
hallmarks of aggressiveness 
 In vivo studies of the effects of small 
molecules selective for FKBP51 on 
tumor growth and invasion, in a mice 
model of glioblastoma. 
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3. MATERIALS AND 
METHODS 
Cell culture: human glioma cell lines 
D54 and U251 were obtained by 
CEINGE cell bank (Cellular Technology 
Platform). This platform guarantees cell 
lines identity and the absence of cross-
contamination and microorganism 
contamination. Cells were cultured at 
37°C and 5% CO2 in DMEM-F12 media 
(Biowest, Nuaillè, France) supplemented 
with 10% foetal bovine serum (FBS; 
Biowest), 200mM glutamine (Lonza), 
and 100 U/ml penicillin-streptomycin 
(Lonza). Human glioma cell line SF767 
was kindly provided by Prof. Gerolama 
Condorelli (University of Naples, 
Federico II) and cultured at 37°C and 5% 
CO2 in DMEM media (Biowest, Nuaillè, 
France) supplemented with 10% foetal 
bovine serum (FBS; Biowest), 200mM 
glutamine (Lonza), and 100 U/ml 
penicillin-streptomycin (Lonza).  
GBM primary cell line GB138, 
established from acutely resected human 
GBM and validated as previous ly 
described (Kroonen et al. 2011) and 
glioma cell line U87MG from American 
Type Culture Collection (ATCC), were 
cultured in DMEM containing 10% FBS, 
200mM glutamine, and 100 U/ml 
penicillin-streptomycin. U87MG cells 
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were isolated from the tumor mass 
(U87MG TM cells) and from the SVZ 
(U87MG SVZ cells) of GBM-
xenografted mice. Briefly, U87MG TM 
and SVZ were isolated from 400uM 
thickness sections obtained with a Leica 
vibratome (Leica VT1000S, Groot 
Bijgaarden, Belgium). Brain slices were 
incubated in papain (WothingtonV R, 
Lakewood, NJ, USA) for 30 min at 37 °C, 
suspended in ovomucoide (WothingtonV 
R) to stop the dissociation and established 
in culture. 
Melanoma cell line SAN was kindly 
provided by Dr. Gabriella Zupi 
(Experimental Preclinic, Regina Elena 
Insitute for Cancer Research, Roma, 
Italy): the cells derive from a patient’s 
tumor lymphonodal metastasis and were 
cultured in RPMI (Lonza, Braine-
l’Alleud, Belgium) supplemented with 
10% foetal bovine serum, 200mM 
glutamine, and 100 U/ml penicill in-
streptomycin. A375 melanoma cell line 
derived from a metastatic tumor and was 
cultured at 37°C and 5% CO2 in DMEM 
supplemented with 15% FKBP, 100 U/ml 
penicillin-streptomycin and 200mM 
glutamine. 
Transfection: K2 transfection System 
(Biontex, Munich, Germany) was used to 
perform overexpression and knockdown 
experiments. According to 
manufacturer’s instructions, 24 hours 
before transfection, 4 x 105 cells were 
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seeded into six-well plates to obtain 80-
90% confluence at the time of 
transfection. Any treatment was 
performed 24 hours after transfection. For 
overexpressing FKBP51s, a True-ORF-
Myc-DDK-tagged expression vector was 
used (OriGen Technologies, Rockville, 
MD, USA), that carried the cDNA of 
FKBP5 transcript variant 4. Control cells 
were transfected with a relative void 
vector. For knockdown, cells were 
transfected with specific short-interfer ing 
oligoribonucleotide  (siRNA) or with a 
nonsilencing siRNA (NS RNA) as 
control, used at a final concentration of 
50nM. NR RNA and siRNA for PD-L1 
were purchased from Novus Biologica l 
(Littleton, CO, USA). For FKBP51s 
siRNA, siRNA#1 and #2 were drawn 
using target sequences at the 3’-coding 
region (between 700 and 1100 bp), while 
siRNA#3 is directed to 3’-UTR (region 
between 5200 and 5800 bp).  
Treatments and reagents: for treatment 
with ionizing radiation (IR), was used a 6 
MV X-ray of a linear accelerator (Primus, 
Siemens, München, Deutschland ). 
SAFit1 and 2 were provided by Prof. 
Felix Hausch laboratory (Gaali et al. 
2015). Nivolumab (BMS-936558; 
Bristol-Myers Squibb, Princeton, NJ, 
USA) was used as anti-PD1 in co-cultures 
experiments. For experiments with SAFit 
compounds (50 μM in DMSO stock 
solution), 1:1000 DMSO:DMEM-F12 
media was used for control cells. 
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Cycloheximide (Sigma-Aldrich) was 
used at the concentration of 20 μg/ml.  
Immunoblot and 
Immunoprecipitation: proteins were 
extracted by the cell using modified RIPA 
buffer (150mM sodiumchloride, 50mM 
Tris-HCl, pH 7.4, 1mM ethylenediamine 
tetraacetic acid (EDTA), 1mM 
phenylmethylsulfonyl fluorite (PMSF), 
1% Triton X-100, 1% sodium 
deoxycholic acid, 0.1% sodium 
dodecylsulfate (SDS), 5 mg/ml aprotinin, 
and 5 mg/ml leupeptin) and run in SDS 
page for immunoplot analysis. The 
primary antibodies against FKBP51 
(rabbit polyclonal; Novus Biologica l), 
FKBP51s (rabbit polyclonal of our 
production, designed against protein C-
terminus) and CD274/PD-L1 (rabbit 
polyclonal; Novus Biological) were used 
diluted 1:2500. CD133 (rabbit 
polyclonal; AbcamVR) was used diluted 
1:1000. A further antibody Pdcd-1L1 
(rabbit polyclonal, Santa Cruz 
Biotechnology) was used for PD-L1 
detection diluted 1:1000. M2-Flag 
(mouse monoclonal; Sigma-Aldrich), γ-
Tubulin (mouse monoclonal; Sigma-
Aldrich) w used diluted 1:5000. Anti-
G3PDH (rabbit monoclonal; Cell 
Signaling), anti-phospho S6 kinase 
(rabbit polyclonal; Cell Signaling) were 
used diluted 1:1000. Anti p70 S6 kinase a 
(rabbit polyclona; Santa Cruz) was used 
diluted 1:500. Anti β-Actin-Peroxidase 
(mouse monoclonal; Sigma-Adrich) was 
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used diluted 1:10000. Antibodies against 
TGN46 (rabbit polyclonal; Sigma-
Aldrich; diluted 1:1000), Calnexin 
(mouse monoclonal; Invitrogen; diluted 
1:1000) and Histone H1 (mouse 
monoclonal; Santa Cruz Biotechnology; 
diluted 1:500) were used as Trans Golgi 
Network (TGN), endoplasmic reticulum 
(ER) and nucleus markers respective ly. 
Anti-Phospho-Akt (Ser473) (rabbit 
monoclonal;Cell Signaling) and Akt1/2/3 
(rabbit polyclonal, Santa Cruz) were used 
diluted 1:1000. For co-
immunoprecipitation of PD-L1 and 
FKBP51s, 500ug of total lysate was pre-
cleared for 1h at 4°C with rotation. Next, 
1ug of each specific antibody was added 
to the lysate and incubated overnight at 
4°C in rotation. Twenty microliters of 
Protein A-Agarose (Santa Cruz 
Biotechnology) was added to the solution 
and precipitation took place for 2h, with 
rotation at 4°C. After washing with 
modified RIPA buffer, samples were 
separated by SDS-PAGE and PD-L1 and 
FKBP51s were analysed by immunoblot. 
Immunostaining: Before the 
immunostaining, cells were seeded for 3h 
on coverslips coated with polyornitihine 
(0.1 mg/ml), then, after washing with 
PBS the cells were fixed in 4% PFA for 
15 minutes. Brain coronal sections or 
cells on coverslips were permeabilized 
and unspecific binding sites were blocked 
for an hour at room temperature using a 
10% donkey serum and 0.1% Triton X-
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100 PBS solution. Tissue sections or 
coverslipped cells were then incubated 
overnight at 4°C with primary antibodies 
diluted in PBS containing 0.1% of 
donkey serum and 0.1% of Triton X-100. 
Primary antibodies were diluted in PBS 
containing 0.1% donkey serum and 0.1% 
Triton X-100, followed by RRX- or 
FITC- conjugated secondary antibodies 
(Jackson Immunoresearch Laboratories; 
diluted 1:500). Anti Ki-67 (BD 
Biosciences) was used diluted 1:500. Anti 
FKBP51s (mouse monoclonal of our 
production) was used diluted 1:80. Anti 
Vimentin (rabbit monoclonal IgG, diluted 
1:400, Cell Signaling®). Brain slides 
were incubated for an hour at RT with 
RRX-conjugated secondary antibody 
(1/500, Jackson Immunoresearch 
Laboratories®) and finally coverslipped 
in a mounting solution containing DAPI 
(Vectashield®). For quantification of 
Vimentin expression in brain slices using 
ImageJ ®, cells GFP+Vimentin+ were 
quantified giving a threshold  calculated 
on the negative control.  
Image acquisition: Immunostained cells 
were imaged using a Zeiss Axiovert 
10VR microscope (Car Zeiss®) coupled 
with Mercator® software (Explora 
Nova®). Figures were examined using 
ImageJ®. 
Glycosidase digestion: after PD-L1 
immunoprecipitation, protein lysates 
were treated with buffer containing N-
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Glycosidase F (PGNase F; CalBiochem 
Deglycosylation Kit, Merck Millipore, 
Temecula, CA) according to the 
manufacturer’s instructions. Digested 
samples were then analysed by 
immunoblot. 
Sub-cellular fractionation: it was 
performed according to Sarnataro et al. 
(Sarnataro et al. 2004) with some 
changes. Briefly, cells were resuspended 
in 800 ul of Buffer F (0.25M sucrose, 
10mM HEPES-NaOH pH 7.2, 10 mM 
KAc, 1.5 mM MgAc) and homogenized 
by pipetting the solution up and down 8-
10 times through a 22-gauge needle. The 
nuclear fraction was sedimented by 
centrifugation for 5 min at 600g and then 
resuspended in modified RIPA buffer. 
The post-nuclear supernatant was 
adjusted to 0.75M sucrose, and the ER 
fraction was sedimented by 
ultracentrifugation for 12 min at 16.000 
rpm at 4°C, in a Beckman Ultracentrifuge 
with an SW 50.1 Ti rotor and resuspended 
in modified RIPA buffer. Golgi fraction 
was obtained in the supernatant. 
Thenafter, all sub-cellular fractions were 
analysed by immunoblot. 
qPCR: total RNA was extracted from 
cells by Trizol (Invitrogen, Carlsbad, CA, 
USA). Each RNA was used for cDNA 
synthesis with iScript Reverse 
Transcription (Bio-Rad, CA, USA). 
Relative gene expression was quantified 
by qPCR with 2-ΔCt comparative method 
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(Schmittgen et al. 2008), using the 
SsoAdvancedTM SYBR Green Supermix 
(Bio-Rad) and specific qPCR primers. To 
amplify FKBP51s, validated QuantiTec 
primers from Qiagen (Valencia, CA, 
USA) were used. Primers to detect PD-L1 
are Fw 5’-
GCTTTTCAATGTGACCAGCA-3’ and 
Rev 5’-
TGGCTCCCAGCCTTACCAAG-3’. 
Relative quantification was performed 
co-amplifying ribosomal 18S (Fw 5’-
CGATGCGGCGGCGTTATTC-3’ and 
Rev 5’-
TCTGTCAATCCTGTCCGTGTCC-3’), 
GAPDH (Fw 5’-
GGACTCATGACCACAGTCCAT-3’ 
and Rev 5’-
GTTCAGCTCAGGGATGACCTT-3’) 
and -Actin (Fw 5’-
CGAGGCCCAGAGCAAGAGAG-3’ 
and Rev 5’-
CGGTTGGCCTTAGGGTTCAG-3’) as 
an internal control for normalization. 
Co-cultures of glioblastoma cells and 
peripheral blood mononuclear cells 
(PBMCs): co-cultures were performed as 
described (Liu et al. 2009; 
Somasundaram et al. 1995). Briefly, 24 h 
before co-culture, 4 x 105 glioblastoma 
cells were plated in 35mm plate. Before 
adding PBMCs, adherent cells were 
washed three times with PBS. PBMCs 
were isolated from heparinized blood by 
a Ficoll-Hypaque density gradient and 
pre-activated with anti-CD3 
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(eBioscience, San Diego, CA,USA) used 
at concentration of 5 μg/ml. After 16h, 1 
x 106/ml PBMCs were added into each 
glioma cells-precoated plate. Cells were 
co-cultured at 37°C in a 5% CO2 
humidified atmosphere in the presence of 
5 μg/ml anti-PD1 or Abiciximab (anti-β3 
integrin as control for humanized 
antibody). For co-culture with SAFit, 
glioma cells were pre-treated with 40 nM 
SAFit1or 60nM SAFit2 for 12h, before 
adding the PBMCs. For co-cultures with 
PD-L1 silencing, PBMCs were added to 
glioma cells after 24h the transfect ion 
took place. After 6h of co-culture, cells in 
suspension were collected and apoptosis 
was assayed by flow cytometry. 
Flow Cytometry: samples were analysed 
by using a BD AccuriTM C6 Cytometer 
(BD Biosciences, New Jersey, USA). PD-
L1 expression was analysed using anti 
B7/H1-phycoerythrin (PE) (R&D 
Systems, Minneapolis, MN, USA) at a 
concentration of 0.05 ug/ml. As control of 
non-specific binding, an Ig isotype PE-
conjugated antibody was used. Apoptosis 
was analysed by annexin-V staining in 
double fluorescence with CD45-Peridinin 
Chlorophyll Protein Complex (PerCP) 
conjugated. Briefly, after co-culture 1 x 
105 cells were harvested and resuspended 
in 100ul of Binding Buffer (10uM 
HEPES/NaOH pH 7.5, 140 uM NaCl and 
2.5 uM CaCl2) containing 1 μl of 
annexin-V-FITC (Pharmigen/Bec ton 
Dickinson, San Diego, CA, USA) and 5 
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μl of CD45. After 15min of incubation at 
room temperature in the dark, 100 μl of 
Binding Buffer was added and apoptosis 
was analysed. 
Intracranial Transplantation: Crl:NU-
Foxn1nu mice were anesthetized with an 
intraperitoneal injection of ketamine (50 
mg/mL, Pfizer®, Bruxelle s, 
Belgium)/xylazine (Sedativum 2%, 
Bayer®, Bruxelles, Belgium) solution 
(V/V). The cranium was exposed and a 
small hole was drilled 2.5 mm lateral and 
0.5 mm anterior to the bregma with a size 
34 inverted cone burr (Dremel). Mice 
were positioned in a stereotactic frame 
and 50,000 GFP+luc+ U87 cells in 2 µl 
PBS were injected into the right striatum 
through a 27-gauge needle over 1 min at 
3 mm below the dura mater. The incis ion 
was closed with Vetbond (3M). 
Mice treatment with SAFit2: The 
treatment was performed as previous ly 
described (Gaali et al. 2015). Briefly, 
animals were daily injected 
intraperitoneally with 10 mg per kg body 
weight of SAFit2 solubilized in a vehicle 
composed of 4% EtOH, 5% Tween80, 
5% PEG400 in 0.9% saline, or just the 
vehicle. 
Processing of Tissue Sections before 
Immunostainings: Mice were 
anaesthetized with an injection of 
Nembutal® (Pentobarbital 60 mg/mL, 
Ceva Sante Animal®) before an 
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intracardiac perfusion with a NaCl 0.9% 
solution (VWR International®) followed 
by paraformaldehyde (PFA) 4% at 4°C 
(4,3g/L NaOH, 40g/L paraformaldehyde, 
18.8 g/L NaH2PO4). Brains were 
collected, postfixed in 4% PFA and 
cryoprotected overnight in a solution of 
PBS/sucrose (20%). Brains were frozen 
at -20°C in a 2-methylbutane solution 
(Sigma®) and cut into 14 μm thick 
coronal sections using a cryostat. The 
volume of the tumor formed has been 
evaluated on GFP+ areas using ImageJ ® 
and using the formula V= (length × 
Width^2)/2.       
Plasmids, lentiviral vectors generation 
and transduction: Gene transfer 
lentiviral plasmid was pLenti6-eGFP-
IRES-Luc. This plasmid allows the dual 
eGFP and firefly luciferase (Photinus 
pyralis) expression and was generated by 
cloning the eGFP sequence and the IRES 
of the encephalomyocarditis virus 
(ECMV) sequence (from pIRES2-eGFP 
Vector, Clontech®, Mountain View, CA, 
USA) and Luciferase gene (from pGL3-
Basic, Promega®) into the pLenti6/V5-
D-Topo (Invitrogen®). U87 cells were 
either transduced with lentiviral vectors 
(15 TU/cell) allowing the dual expression 
of eGFP and luciferase. Transduced cells 
were selected with 1mg/mL Blasticid in 
(Sigma®).  
ER Co-localization Assay: For the 
staining of endoplasmic reticulum I used 
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an organic probe that spontaneously 
localize in the endoplasmic reticulum. 
The ER Staining Kit - Green 
Fluorescence - Cytopainter (ab139481) 
was used following manufacturer’s 
instructions. The quantification of co-
localized ER-FKBP51s signal was 
performed using ImageJ®: on the merged 
picture, the amount of co-localized 
FKBP51s with the ER staining was 
quantified measuring the intensity of the 
yellow signal; for the non-colocalized 
FKBP51s, was measured the intensity of 
the red signal.  
Analysis of proliferation status: U87 
cells from TM and SVZ were daily 
treated with 60 nM SAFit2 or the vehicle. 
Every two days the cells were harvested 
and cell number was estimated by 
Countess II Automated Cell Counter. At 
fourth days of treatment: cells were also 
seeded on a coverslips and processed for 
Ki67 immunostaining as previous ly 
described. 
Spheroids formation assay: U87 cells 
from TM and SVZ were cultured in 
DMEM/F12 serum-free medium 
containing B27 without vitamin A (Life 
Technologies®) and supplemented with 
recombinant epidermal growth factor and 
fibroblast growth factor 2 (EGF, 20 
ng/mL and FGF-2, 10 ng/mL, 
Preprotech®). After 4 days in culture, the 
amount of spheroids was counted using 
an optical microscope. 
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Statistical Analysis: Student’s t-test was 
used to analyse differences between 
means of values. ANOVA served to 
compare different experimental groups. 
A p-value ≤ 0.05 was considered 
statistically significant.     
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4. RESULTS 
 
Expression of FKBP51s and PD-L1 in 
glioma cell lines and tumor sections 
I semiquantitatively measured the basal 
expression of FKBP51 isoforms in 
glioma cell lines (D54 and U251) and 
primary glioma cell line GB138, in 
comparison with melanoma cell lines 
(A375 and SAN) by immunoblot. Figure 
1A shows that glioma cells expressed 
both canonical and the spliced isoform of 
FKBP51, in particular, the expression of 
FKBP51s showed to be higher in GB138; 
in melanoma cells, FKBP51s was barely 
detectable. I then measured PD-L1 
expression in U251, D54 and GB138 by 
flow cytometry (1B). Results showed that 
glioma cells expressed high levels of PD-
L1 on plasma membrane and the 
expression appeared to be highest in 
GB138. Immunoblot analysis of PD-L1 
on whole protein lysates of U251 and 
D54 revealed the presence of several 
isoforms of the protein (1C). In 
accordance with to Li et al., the higher 
molecular weight isoforms are post-
translationally modified, while the band 
at ~37 kDa corresponds to the naïve 
protein (Li et al. 2106). PD-L1 contains 
four residues of asparagine that are N-
Glycosylated 
(https://www.uniprot.org/uniprot/Q9NZ
Q7#ptm_processing). In addition to  ~37 
kDa band, I found bands at ~50 and ~68 
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kDa.  I analysed PD-L1 expression by 
immunoblot also in GB138 in 
comparison to melanoma cell lines A375 
and SAN (Figure 1C). While in A375 and 
SAN, PD-L1 was barely detected, in line 
with previous results (Romano, 
D’Angelillo, Staibano et al. 2015);  in 
GB138, the 50 kDa modified isoform of 
PD-L1 appeared to be highly expressed, 
while the naïve band was not appreciated. 
To confirm that higher isoforms of PD-L1 
are glycosylated, I treated 
immunoprecipitated PD-L1 protein with 
an N-Glycosidase, PNGase F. As shown 
in Figure 1E, treatment with PGNase F 
caused a decreasing of 68-kDa band and 
a concomitant appearance of a ~37 kDa 
band of PD-L1, suggesting that 68 kDa 
band is N-glycosylated. Because the 
glycosylation process occurs in the lumen 
of endoplasmic reticulum (ER) and in 
Golgi cisternae, by fractionation of D54 
cells, I obtained protein extracts from 
different sub-cellular compartments that 
were analysed by immunoblot for the 
presence of FKBP51, FKBP51s and PD-
L1 isoforms. Figure 1F shows that 68 kDa 
band is expressed in the ER and mostly in 
the Golgi fraction, 50 kDa band is 
appreciable in the Golgi fraction. 
Interestingly, FKBP51s and not FKBP51 
was expressed in the ER fraction, 
suggesting a possible role in the ER that 
distinguishes the shorter isoform from the 
canonical one. In collaboration with the 
Pathologists of our University, 
expression of FKBP51s and PD-L1 was 
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confirmed in 29 specimens from 
glioblastoma patients by 
immunohistochemistry (IHC) (Figure 
2A-D). Cytoplasmic and nuclear 
FKBP51s expressions of tumor tissue 
were observed. PD-L1 staining was 
observed in glioblastoma tissues to a 
variable extent and intensity. FKBP51s 
expression was also confirmed at mRNA 
level in eight glioblastoma specimens 
(2E). Details on IHC semiquantitat ive 
evaluation are reported in Table 1. 
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Fig 1. Expression of FKBP51s and PD-
L1 in glioma cell lines  
(A) Immunoblot assay of FKBP51 and 
FKBP51s expression in D54, U251 
glioma cell lines and in the primary 
glioblastoma GB138 cells. Lysates 
derived from A375 and SAN melanoma 
cell lines were used for comparison. (B) 
Flow cytometric histograms of PD-L1 
expression in U251, D54 and GB138 
glioblastoma cell lines. (C) Immunob lo t 
analysis of PD-L1 expression in D54 and 
U251: the arrows indicate 3 isoforms of 
the protein ascribable to the naive (37 
kDa) and post-traslational modified 
isoforms (~50 and ~68 kDa). (D) 
Immunoblot assay of PD-L1 expression 
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in primary glioblastoma GB138 cells 
compared to melanoma cell lines A375 
and SAN. (E) Whole D54 lysates 
immunoprecipitated with anti-PD-L1 and 
treated, or not, with PNGase F. The 
arrows indicate the higher, in PGNase 
treated lysates, and lower, in not treated 
lysates, PD-L1 band. Fetuin, on the left of 
the panel, was used as positive control of 
PGNase digestion. (F) Immunoblot of 
D54 lysates obtained from sub-cellula r 
compartments. PD-L1, FKBP51 and 
FKBP51s levels are shown with the 
relative organelle markers.  
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Fig 2. FKBP51s and PD-
L1 immunohistochemistry of glioma 
samples  
FKBP51s cytoplasmic immunoreactivity 
was detected in >10% and <50% (A) or in 
≥50% (B) of neoplastic cells (400x 
magnification). In some cases a strong 
(A) nuclear localization was observed.  
PD-L1 displayed focal signal (≤10%) 
with cytoplasmic and membrane 
immunoreactivity (C; 200x 
magnification) and a strong and diffuse 
signal in neoplastic cells (≥50%), both 
cytoplasmic and nuclear (D; 200x 
magnification). (E) quantitat ive 
FKBP51s expression of 8 glioblastoma 
samples. QPCR was performed by using 
a coamplified β-actin internal control for 
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sample normalization. FKBP51s value of 
a PBMC has been also run for 
comparison. Columns and bars are 
representative of means and standard 
deviations of values for each sample as 
individual data point. 
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Table 1. Profiles of FKBP51s and PD-
L1 expression in 29 cases of 
glioblastoma multiforme 
* (% x intensity) 
%(proportion of immunoreactive 
neoplastic cells): 1, ≤10%; 2, >10% and 
<50%; 3, ≥50% 
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Intensity: 1, weak: the signal was evident 
only at 40x magnification; 2, moderate: 
the signal was evident at 20x 
magnification; 3, strong: the signal was 
evident at 10x magnification 
 ** +, reaction in ≥5% of tumor cells; -, 
<5% of tumor cells 
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FKBP51s regulates PD-L1 expression 
acting as a co-chaperone in the ER 
To investigate the role of FKBP51s on 
PD-L1 expression, I used different 
FKBP51s siRNAs and a PD-L1 siRNA 
for protein knockdown and then 
evaluated the effect on PD-L1 expression 
by immunoblot. Figure 3A shows that 
FKBP51s silencing is able to decrease 
PD-L1 expression: the isoforms with 
higher molecular weight, in particular the 
68 kDa band, appeared to be down-
modulated especially by the mixture of 
two FKBP51s siRNAs. Surprisingly, 
FKBP51s silencing was also able to affect 
naïve PD-L1 expression. Silencing of 
PD-L1 showed to down-modulate 68 and 
37 kDa bands. As shown in Figure 3B, 
FKBP51s silencing doesn’t reduce 
transcript levels of PD-L1, as it happens 
with PD-L1 silencing, which was used as 
positive control. This result let us  
exclude a transcriptional regulation by 
FKBP51s, giving strength to the 
hypothesis that the protein acts on a post-
translational level. The effect on naïve 
PD-L1 is probably related to ER stress 
due to an imbalance of ER-related 
proteins. Flow cytometry results 
confirmed that FKBP51s silencing is able 
to decrease PD-L1 expression on plasma 
membrane (Figure 3C). A representative 
PD-L1 histogram in overlay from 
silencing experiment is shown in Figure 
3D. To further confirm the role of 
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FKBP51s on PD-L1 expression, I also 
performed an over-expression of 
FKBP51s in U251 and D54 cells, then I 
analysed PD-L1 level by immunob lo t 
(Figure 3E). As expected, higher 
molecular weight bands at 68 and 50 kDa 
showed to be increased by the over-
expression of FKBP51s. Because 
FKBP51s was found in ER together with 
naïve and modified PD-L1 isoforms, I 
investigated a possible interact ion 
between the two proteins in ER. As 
shown in Figure 3F, pull-down of either 
FKBP51s and PD-L1 confirmed that the 
two proteins interact with each other in 
the ER fraction. 
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Fig 3. FKBP51s regulates PD-L1 
expression acting as a co-chaperone in 
the ER 
(A) Immunoblot of lysates obtained from 
glioblastoma cell line U251, transfected 
with FKBP51s siRNAs, PD-L1 sirna or a 
non-silencing (NS) RNA. (B) qPCR 
analysis of PD-L1 and FKBP51s 
expression in U251 and D54 
glioblastoma cells, transfected with NS 
RNA, FKBP51s siRNA mix, PD-L1 
siRNA (upper) or a vector carrying 
FKBP51s or an empty vector as control 
(lower). (C) U251 cells treated as in A, 
were analysed by flow cytometry for PD-
L1 expression. The graph represents MFI 
(mean and standard deviation) of PDL1 
expression. P values are indicated (N=6). 
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(D) Flow cytometric histograms shown in 
overlay of PD-L1 expression in U251 
glioma cells, silenced or not for FKBP51s 
, or PD-L1. (E) Immunoblot of cell 
lysates obtained from D54 and U251 
glioblastoma cell lines over-expressing 
FKBP51s or transfected with a void 
vector (EV) as control.  (F) Co-IP of PD-
L1 and FKBP51s in ER fraction. ER 
lysates were immunoprecipitated with 
anti-PD-L1 and anti-FKBP51s and 
analysed for proteins presence by 
immunoblot. 
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Selective inhibition of FKBP51s by 
SAFit reduces PD-L1 expression 
Because SAFits, the selective inhibitors 
of FKBP51, were designed to interact 
with the FK1 domain (Gaali et al. 2016), 
which is retained in FKBP51s, I 
investigated their ability to modulate PD-
L1 expression in glioma. Figure 4A 
shows a dose-response assay of SAFit 
effect on PD-L1, as measured by flow 
cytometry. After 12 hours of treatment 
with three different doses of SAFit1 and 
SAFit2 (5, 25 or 50nM), I found that 
especially SAFit2 was able to decrease 
PD-L1 expression on plasma membrane. 
Figure 4B shows a kinetic of PD-L1 
expression regulation by SAFit2. Results 
confirmed that after 12 hours the drug 
significantly decreased the expression of 
PD-L1 on plasma membrane. A 
representative histogram in overlay of 
flow cytometry analysis (Figure 4C), 
shows the down-modulation of  PD-L1 by 
SAFit2 treatment. Immunoblot analysis 
of PD-L1 expression after SAFit2 
treatment (Figure 4D) shows that the 
modified isoforms of the protein are 
affected by the drug treatment. 
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Fig 4. Selective inhibition of FKBP51s 
by SAFits reduces PD-L1 expression 
(A) Dose response assay of SAFit on PD-
L1 expression. D54 glioblastoma cells 
were incubated with SAFit1 and 2 at 
different concentrations. After 12h of 
incubation, cells were harvested and 
analysed by flow cytometry for PD-L1 
expression. Graph columns represent 
mean fluorescence itensities of PD-L1 
expression with related P values (N=3). 
(B) Kinetic of PD-L1 expression. 
Glioblastoma cells were treated with 
SAFit2 for different times of incubation, 
then, cells were harvested and analysed 
by flow cytometry for PD-L1 expression. 
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Graph represents mean fluorescence 
intesities of PD-L1 expression (N=3). (C) 
Flow cytometric histograms represented 
in overlay and immunoblot (D) of PD-L1 
expression in cells cultured in absence or 
presence of 50nM SAFit2 for 12h.  
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SAFit impairs PD-L1 up-regulation 
induced by ionizing radiation 
Because ionizing radiation (IR) induces 
PD-L1 expression in glioma cells (Song 
et al. 2018), I investigated whether 
treatment with SAFit2 was able to impair 
such an induction. As shown in Figure 
5A, by flow cytometry, I measured a 
significant induction of PD-L1 
expression with 4 and 8Gy IR (p=0.05), 
which was dampened by SAFit2. The IR-
induced up-regulation was also measured 
at mRNA level (Figure 5B). By 
immunoblot of protein lysates from D54 
cells collected after IR in kinetic (Figure 
5C), It can be appreciated that the 
induction of 68 kDa isoform of PD-L1 is 
impaired by SAFit2. A decreasing of 
naïve 37 kDa isoform of PD-L1 was also 
appreciated with SAFit2 after 24 hours of 
irradiation, suggesting that in particula r 
conditions the drug can also affect the 
level of naïve protein. By RNA silencing, 
I further analysed the role of FKBP51s on 
PD-L1 induction after IR treatment. As 
shown in the immunoblot of Figure 5D, 
D54 cells silenced for FKBP51s did not 
show the increase of the 68kDa PD-L1 
band after IR. Sub-cellular fractionation 
of D54 cells treated with IR (Figure 5E) 
showed that, after 12 hours from IR, a 
PD-L1 isoform between 37 and 50 kDa is 
strongly induced. The same PD-L1 
isoform induced in the ER decreased after 
24 hours from IR. In the Golgi fraction, 
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the expression of 68 kDa PD-L1 band 
appeared to increase after 12 h from IR 
and did not substantially change after 
24h. Expression of FKBP51s in the ER, 
after a strong decreasing at 3 hours from 
IR, showed to be induced at 12 hours 
from the treatment. The same sub-cellula r 
fractionation experiment, performed in 
the presence of SAFit2 (Figure 5F), 
showed that after 12 hours from IR, the 
drug was able to attenuate the induction 
of both PD-L1 isoform up to 37 kDa in 
the ER and the higher isoform in the 
Golgi fraction. Because AKT activity in 
glioma cells has shown to induce PD-L1 
expression by a post-transcriptiona l 
mechanism (Parsa et al. 2007), I 
investigated the levels of phospho-AKT 
in both whole protein lysates and ER 
fraction of D54 cells treated with IR 
(Figure 5G). Immunoblot on whole 
lysates showed that pAKT levels are 
induced by irradiation and remain high 
until 12 hours from treatment, after that 
pAKT levels showed to be decreased. 
Furthermore, I found high levels of 
pAKT in the ER, confirming an important 
function for this protein in ER 
membranes (Du et al. 2006).  
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Fig 5. SAFit2 impairs PD-L1 up-
regulation by ionizing radiations 
treatment 
(A) Dose response assay of IR-induced 
PD-L1 expression and modulation by 
SAFit2. D54 glioblastoma cells were 
irradiated at different Gy doses (1, 4 and 
8Gy), in the absence or presence of 50 nM 
SAFit1 aor SAFit2. After 12h of 
incubation, cells were harvested and 
analysed by flow cytometry for PD-L1 
expression. The graph represents mean 
fluorescence intensities (mean and 
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standard deviation, N=3) of PD-L1 
expression. (B) PD-L1 mRNA expression 
levels analysis by qPCR in D54 glioma 
cells, after  irradiation at 4 and 8 Gy. Cells 
were harvested 12h after IR. (C) Kinetic 
of IR-induced PD-L1 expression levels. 
D54 cells were harvested 3, 12, 24h after 
4 Gy IR. (D) Immunoblot assay of PD-L1 
expression in cell lysates obtained from 
D54 glioblastoma cells, transfected with 
a FKBP51s siRNAs mix, or NS RNA, 
24h before irradiation at 4 Gy. Cells were 
harvested 12h after IR. (E) Immunob lo t 
of lysates obtained from sub-cellula r 
compartments of D54 cells after 4 Gy IR. 
PD-L1 and FKBP51s levels are shown 
along with relative organelle markers. 
(G) p-AKT expression levels in D54 
lysates obtained from whole cell and ER 
compartment, shown along with ER 
marker.     
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SAFit reduces PD-L1-induced cell death 
of PBMC co-cultured with glioma cells 
To investigate whether SAFits treatment 
could affect glioma cells capacity to kill 
lymphocytes through PD-L1/PD1 
interaction, as previously described 
(Romano, D’Angelillo, Staibano et al. 
2015), I performed co-cultures of 
glioblastoma cells with peripheral blood 
mononuclear cells (PBMC) isolated from 
healthy donors. To this end, besides U251 
and D54 glioma cells that were highly 
positive for PD-L1, I also used another 
glioma cell line, SF767, that expressed 
very low levels of PD-L1 as shown by 
flow cytometry (Figure 6A) and 
immunoblot analysis (Figure 6B). 
PBMCs were harvested after 6 hours of 
co-culture and apoptosis was analysed by 
annexin V staining in double 
fluorescence with CD45, in flow 
cytometry. Only cells positive for CD45 
were taken into account for the analysis, 
to exclude any presence of non-PBMCs 
cells, results are represented in (Figure 
6C). PBMC co-cultured with glioma cells 
showed a significant increase in apoptosis 
compared with non-co-cultured cells 
(Figure 6C). PD-L1 silencing of glioma 
cells significantly reduced the extent of 
cell death in co-cultured PBMC, with 
exception of SF767 co-cultures (Figure 
6C). A similar decrease in PBMC 
apoptosis was measured when anti-PD1 
or SAFits was added to the co-cultures 
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(Figure 6D). Such treatments produced a 
decrease in cell death of PBMCs co-
cultured with D54 and U251, compared 
to apoptosis of PBMCs co-cultured in the 
presence of an unrelated monoclona l 
antibody (Abiciximab) (Figure 6D).  Th 
lack of effect observed with PD-L1 
silencing (Figure 6C) or anti-PD1 (Figure 
6D) in SF767 co-cultures  suggests that 
mechanisms other than PD-1/PD-L1 
signal could play a role in SF767-induced 
lymphocyte killing.  
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Fig 6. SAFits reduced PD-L1-induced 
cell death of PBMCs co-cultured with 
glioma cells 
PD-L1 expression in D54, U251 and 
SF767 glioblastoma cells analysed by 
flow cytometry (A) and by immunob lo t 
(B). (C) Graphical representation of cell 
death values of PBMC not cocultured or 
cocultured for 6h with D54, U251, and 
SF767 glioblastoma cells, previous ly 
silenced or not for PD-L1. PBMC was 
harvested and assayed by flow cytometry. 
Values are reported as box plots. 
Differences are shown (N=6) (D) 
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Graphical representation of cell death 
values of PBMC not cocultured (no CC) 
or cocultured (CC/) for 6h with D54, 
U251 and SF767 glioblastoma cells, in  
the absence or presence of anti-PD1, 
SAFit1 and SAFit2 or a humanized 
antibody (Abiciximab)m as control. 
PBMC was harvested and assayed in flow 
cytometry for Annexin-V binding in 
double fluorescence with CD45. Values 
measured for each cell line are reported as 
box plots. Differences (p-values) are 
shown (N=6)  
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Expression of PD-L1 in glioblastoma 
cells from tumor mass (TM) and sub-
ventricular zone (SVZ) 
In collaboration with professor Rogister 
research group from GIGA 
Neurosciences of Liege, I had the 
opportunity to investigate the mechanism 
of post-translational regulation of PD-L1 
expression in glioblastoma cell lines 
obtained by orthotopic injection of 
human U87 cells in the striatum of the 
athymic nude mouse. According to this in 
vivo model (Kroonen et al. 2011), after 
four weeks from the cell injection, in 
addition to a tumor mass formed in the 
nigrostriatal region, a group of 
glioblastoma cells, migrating from the 
tumor mass (TM) through the corpus 
callosum, can be recognizable in the 
subventricular zone (SVZ). As previous ly 
discussed, cells from SVZ show 
characteristics of high tumorigenicity if 
re-injected in mouse, suggesting that 
these cells are particularly enriched in  
GICs. The two formed glioblastoma 
subsets from TM and SVZ were isolated 
by Rogister group, in order to establish 
two different cell lines for in vitro studies.   
As sown in Figure 7A, expression of 
glycosylated PD-L1 in the SVZ was 
higher than the TM. Immunoblot of 
Figure 7A also shows that SVZ expressed 
higher levels of the glioma stem marker, 
CD133 (Brescia et al. 2013), in 
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accordance with the notion that these 
cells had a more stem phenotype than 
cells from TM. Flow cytometry analysis 
(Figure 7B) confirmed that PD-L1 
expression on plasma membrane was 
higher in cells from SVZ than from TM. 
Figure 7C shows a representative 
histogram in overlay of flow cytometry 
analysis of PD-L1 expression on TM and 
SVZ. By qPCR, I measured mRNA levels 
of PD-L1 (Figure 7D): transcript levels of 
PD-L1 showed to be even higher in the 
TM in comparison with SVZ, suggest ing 
that the higher protein level in SVZ was 
ascribable to post-transcriptiona l 
mechanisms of regulation. In line with 
Parsa (Parsa et al. 2007), I measured 
increased AKT and S6K1 
phosphorylation levels in the SVZ than 
TM, suggesting an involvement of this 
signaling pathway in the increased PD-L1 
level in SVZ, notwithstanding the 
reduced PD-L1 transcript levels. 
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Fig 7. Expression of PD-L1 in 
glioblastoma cells from tumor mass 
(TM) and sub-ventricular zone (SVZ) 
(A) Immunoblot of the expression of PD-
L1 and CD133 in U87 derived from TM 
and SVZ. (B) Flow cytometry analysis of 
PD-L1 expression in glioblastoma cells 
from TM and SVZ. Graph columns 
represents mean fluorescence intensit ie s 
with related P value (N=3) and a 
representative histogram showed in 
overlay (C) of PD-L1 expression in SVZ 
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and TM cells. (D) qPCR analysis of 
mRNA levels of PD-L1 in TM and SVZ 
cells. Graph columns represents 
normalized quantification relative to TM. 
(E) Analysis of p-AKT and p-S6K1 with 
related total proteins and γ-tubulin as 
normalizer. 
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Expression of PD-L1 in SVZ cells is 
particularly sensitive to FKBP51s 
modulation 
To address whether FKBP51s had a role 
in PD-L1 expression, by RNA silencing I 
down-modulated FKBP51s in cells from 
TM and SVZ and then compared PD-L1 
expression with that of cells transfected 
with a scrambled RNA. Immunob lo t 
(Figure 8A) and flow cytometry analysis 
of PD-L1 expression (Figure 8B) showed 
that in both TM and SVZ, down-
modulation of FKBP51s decreased PD-
L1 expression. I then investigated 
whether the effect of FKBP51s silenc ing 
was reproduced by the specific inhibito r 
SAFit2. To this end, I treated U87 cells 
from TM and SVZ with SAFit2  and 
analysed PD-L1 expression by flow 
cytometry (Figure 8C). I found that 
SAFit2 was able to remarkably decrease 
PD-L1 expression on plasma membrane 
in cells from SVZ. The effect of SAFit2 
on PD-L1 downmodulation was less 
remarkable although significant on TM 
cells. 
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Fig 8. Expression of PD-L1 in SVZ cells 
is particularly sensitive to FKBP51s 
modulation 
(A) Analysis of PD-L1 expression in cells 
from TM and SVZ silenced for FKBP51s 
and with a NS RNA. Expression of 
FKBP51s is shown to validate the 
silencing of the protein, while the 
expression of FKBP51 shows the 
specificity of the siRNA used. (B) Floy 
cytometry analysis of PD-L1 expression 
in cells from TM and SVZ silenced for 
FKBP51s and for NS RNA as control. 
Graph columns represent mean 
fluorescence intensities of PD-L1 
expression relative to the NS with related 
P values (N=3). (C) Expression of PD-L1 
by flow cytometry in cells from TM and 
SVZ treated with 60 nM SAFit2 or with 
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the vehicle. After 12 hours of treament 
cells were harvested and stained for the 
analysis. Graph columns represent 
percentage of PD-L1 expression relative 
to NT cells.      
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FKBP51s in SVZ cells is mainly 
localized in the ER 
I analysed FKBP51s co-localization with 
an endoplasmic reticulum marker, by 
immunofluorescence microscopy (Figure 
9A). I measured the percentage of 
FKBP51s that co-localized with the ER 
probe and found that it was higher in SVZ 
than TM (Figure 9A right). Because 
proteins from the ER are subjected to a 
rapid turnover through a mechanism of 
selective autophagy (Khaminets et al. 
2015), I attempted to address the turnover 
of FKBP51s using cycloheximide, an 
inhibitor of protein synthesis. Proteins 
with a low turnover and a high stability 
are, indeed, poorly influenced in their 
expression levels by protein synthesis 
inhibition. I firstly analysed FKBP51s 
level in TM and SVZ cells following 
treatment with cycloheximide (Figure 
9B). After 4 hours of incubation, 
immunoblot showed that FKBP51s in 
SVZ cell was significantly decreased, 
whereas its expression level in TM cells 
did not appear to be reduced in 
comparison with untreated cells. This 
result suggested a more rapid turnover of 
FKBP51s in SVZ cells, as it occurs for 
ER-associated proteins. 
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Fig 9. FKBP51s in SVZ cells is mainly 
localized in the ER 
(A) Analysis by immunofluorescence of 
FKBP51s, ER staining and nuclei 
staining by DAPI in cells from TM and 
SVZ.  The three fluorescence signals are 
shown in single and merged to address 
colocalization of FKBP51s with nuclei 
and ER compartments. Graph columns, 
shown in the right of the picture, 
represent the mean intensity of 
FKBP51s/ER co-localization signa l 
relative to the total FKBP51s expression 
per cell, measured by ImageJ®. (B) 
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Immunoblot analysis of FKBP51s 
expression in TM and SVZ cells, treated 
and not treated for 4 hours with 
cycloheximide. Expression of p53 is 
shown as a positive control of 
cycloheximide effect. γ-tubulin 
expression is shown for protein 
normalization.     
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FKBP51s and PD-L1 sustain 
glioblastoma capacity to form 
spheroids 
Because, in melanoma, PD-L1 has 
demonstrated to be an important 
promoter of self-renewal and 
proliferation of the“malignant melanoma 
initiating cells” (Zheng et al. 2017), I 
performed a spheroid assay to address 
whether, by modulating the expression of 
PD-L1 or FKBP51s, I was able to 
influence the ability of U87 cells from 
TM and SVZ to form floating spheres. As 
expected, SVZ cells had an increased 
capacity to form spheroids in comparison 
with TM cells, in line with the higher 
GICs characteristics of these SVZ cells 
(Figure 10A). In both TM and SVZ, 
modulation of PD-L1 and FKBP51s 
expression by RNA silencing produced a 
decrease in cell capacity to form 
spheroids, in comparison with cells 
transfected with a scrambled RNA 
(Figure 10B). The silencing of PD-L1 
was assessed in flow cytometry. Figure 
10C shows representatives flow 
cytometry histograms in overlay of PD-
L1 expression (left) and MFI 
quantification of PD-L1 expression 
(right) showed the effective down-
modulation of the protein in silenced cells 
from TM and SVZ. The spheroid assay 
was also performed treating cells from 
TM and SVZ with SAFit2 (Figure 10D): 
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the drug demonstrated to be able to 
decrease cell capacity to form spheroids.  
 
 
Fig 10. FKBP51s and PD-L1 expression 
sustain glioblastoma capacity to form 
shperoids 
(A) Analysis of spheroid formation in TM 
and SVZ cells in basal condition. Graph 
columns represent spheroid number 
relative to TM. Representative pictures of 
spheroids formed in lower part of the 
picture. (B) Spheroid assay with cells 
from TM and SVZ silenced for FKBP51s, 
for PD-L1 or transfected with a NS RNA 
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as a negative control. Graph columns 
represent the spheroid number after 4 
days in culture relative to NS RNA-
treated cells. Representative pictures of 
spheroids formed taken by optical 
microscope in the lower part of the 
picture. (C) Histograms represented in 
overlay of PD-L1 expression in TM and 
SVZ cells silenced for PD-L1 with related 
IgG negative control. On the left of the 
picture, a graph columns represent mean 
fluorescence intensities of PD-L1 
expression relative to NS.   (D) Analysis 
of spheroid formation in TM and SVZ 
cells daily treated with 60nM SAFit2 or 
the vehicle. Graph columns represent 
formed spheroids number after 4 days in 
culture in the presence or not with 
SAFit2. Representative pictures of 
spheroids taken by optical microscope in 
the lower part of the picture. 
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SAFit impairs glioblastoma cell 
proliferation  
To address whether SAFit2 impaired the 
proliferation capacity of cells from TM 
and SVZ, I analysed by 
immunofluorescence the expression of 
Ki67 in cells treated with the drug 
compared with expression in untreated 
cells. Figure 11A shows that, in cells 
from both TM and SVZ, a 4-day 
treatment with SAFit2 significantly 
decreased Ki67 expression. In addition, 
using an automated cell counter, I 
confirmed that a daily stimulation with 
SAFit2 affected the proliferation capacity 
of cells from TM and SVZ, especially 
after 8 days (Figure 11B). 
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Fig 11. SAFit2 impairs glioblastoma 
cells proliferation capacity  
(A) Ki67 expression measured by 
immunefluorescence in cells from TM 
and SVZ treated with 60nM SAFit2 or the 
vehicle. In the lower part of the picture: 
graph columns represents percentage of 
Ki67 positive cells relative to NT. Related 
P values are shown (N=3). Representative 
pictures of Ki67 alone or merged with 
nuclei staining with DAPI. (B) Dot plots 
representing the counting of TM and SVZ 
cells treated with 60 nM SAFit2 or with 
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the vehicle. A significative differences in 
cell numbers measured at 8 days of 
treatment are represented with related P 
values (N=3). 
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SAFit decreases tumor volume and 
aggressiveness in a mice model of 
glioblastoma   
Encouraged by in vitro results, I 
approached an orthotopic mouse model 
of glioblastoma to investigate the effect 
of SAFit2 treatment against the tumor. 
U87 cells were injected in 16 mice brains 
and after two weeks, during which tumor 
cells formed a tumor mass in the 
nigrostriatal region, 8 mice were daily 
treated with SAFit2 by intra-peritonea l 
injection. U87 cells injected expressed 
the green fluorescence protein (GFP) and 
the luciferase reporter gene. The drug was 
dissolved in a vehicle designed to pass 
through the hematoencephalic barrier. 
After two weeks of treatment 
(corresponding to four weeks from the 
injection of the cells) the mice were 
sacrificed and the brains obtained. I 
measured the volume of the tumor mass 
and analysed the expression of vimentin, 
a marker of tumor invasion and 
aggressiveness, on brain slices. I 
calculated a reduced tumor mass in mice 
treated with SAFit2 compared with mice 
treated with the vehicle (Figure 12B). The 
result was also confirmed by a reduced 
luminescence intensity (Figure 12A).  
Moreover, on brain slices, I measured the 
expression of vimentin in GFP+ cells by 
immunofluorescence: results showed that 
the percentage of tumor cells positive for 
the expression of the vimentin was 
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reduced in mice treated with SAFit2 
(Figure 12C). 
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Fig 12. SAFit2 impairs glioblastoma 
tumor growth  
(A) Luciferase assay, performed on mice 
injected with U87 GFP+luc+ cells, 
treated or not treated with SAFit2. On the 
left, three mice from each group are 
shown before starting of the treatment, 
corresponding to 2 weeks after the 
injection of U87 GFP+luc+, and after 10 
days from the starting of the treatment. 
Graph columns, on the right of the 
picture, represents mean values of signa l 
intensities from the two groups before 
and after the treatment. (B) Dot plot 
represents the volumes of the tumor 
formed in 8 mice treated daily with 
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SAFit2 or 8 mice treated with vehicle. 
The bars represent the medians of the 
volumes measured in each group. (C) 
Expression of Vimentin analysed by 
immunofluorescence on brain slices of 
mice treated or not with SAFit2. Also 
nuclei staining with DAPI and GFP are 
represented. A merged picture of 
Vimentin and GFP signals is also shown. 
On the left, graph columns representing 
the percentage of GFP+Vimentin+ cells 
measured by ImageJ® are shown in the 
lower part of the picture. 
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5. DISCUSSION 
 
Glioblastoma is the most dangerous and 
aggressive form of brain cancer. No 
contemporary treatments are curative. So 
far, a number of biologicals with anti-
invasive and antiangiogenic effects or 
inhibitors of specific oncogenic signaling 
pathways have failed to show overall 
survival benefits in this neoplasia. Recent 
advances in cancer immunotherapy have 
raised new hope for the treatment of this 
poor prognosis tumor. Targeting of the 
checkpoint inhibitors of immune system 
represents a promising strategy, currently 
in development also for glioblastoma. 
PD-L1 is one component of such 
inhibitory immune checkpoint proteins 
(Yao et al. 2013). Notwithstanding the 
different results between diverse groups 
reporting percentage of PD-L1 
expressing cells in glioma tumors 
(Nduom et al. 2016; Berghoff et al. 2015), 
there is data in support of a role for PD-
L1 level in influencing the prognosis of 
glioma (Nduom et al. 2016). The 
mechanism involved in regulation of PD-
L1 expression is still poorly understood. 
Starting from previous results obtained in 
melanoma (Romano, D’Angelillo, 
Staibano et al. 2015; Romano et al. 2017) 
that a spliced isoform of FKBP51, 
FKBP51s, was induced after the contact 
of the tumor with the lymphocytes 
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through PD-L1/PD1 and regulated PD-L1 
expression (Romano, D’Angelillo, 
Staibano et al. 2015), I decided to use 
glioblastoma as a model for my PhD 
program aimed at addressing the role of 
FKBP51s in PD-L1 expression regulat ion 
in tumors. The reasons for choosing this 
tumor type reside in the notion that 
gliomas express PD-L1 (Nduom et al. 
2016; Berghoff et al. 2015) along with 
high levels of FKBP51 (Jiang et al. 2008). 
I found that FKBP51s was abundantly 
expressed in glioma cell lines and patient 
specimens. Analysis by 
immunohistochemistry of PD-L1 
together with FKBP51s showed that the 
scores of FKBP51s tended to be increased 
in accordance with PD-L1 scores, which 
generated the hypothesis (to be addressed 
with a larger sample size) that the two 
variables (FKBP51s and PD-L1) might 
be associated. 
In accordance with “The Human Protein 
Atlas” database 
(https://www.proteinatlas.org/ENSG000
00120217-
CD274/tissue/cerebral+cortex), the 
central nervous tissue does not express 
PD-L1 in physiological conditions 
(Uhlen et al. 2015). Nevertheless, a series 
of studies have demonstrated that PD-L1 
is up-regulated in glial cells during 
inflammation (Salama et al. 2003), and in 
neurons during a viral infection (Lafon et 
al. 2008). A work by Liu et al. have 
deeply described, in glioblastoma 
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patients, the expression of PD-L1 in the 
neurons that circumscribe the tumor mass 
(Liu et al. 2013). Research group have 
founded that the induction of PD-L1 
expression in glioma-adjacent brain 
tissue, is frequently associated with a 
tumor mass that poorly expresses PD-L1, 
whereas lack of PD-L1 expression is 
associated with high expressing PD-L1 
gliomas (Liu et al. 2013).        
I also found that FKBP51s interacted with 
PD-L1 in the ER and modulated 
especially the glycosylated isoforms of 
PD-L1, which  suggested that the activity 
of FKBP51s was relevant for the post-
translational processing, reasonably, 
acting as a foldase because of its 
isomerase activity. It is to be noted that 
the correct glycosylation of PD-L1, as the 
most plasma membrane proteins, deeply 
influences the affinity of the ligand for its 
cognate receptor, PD-1 (Cheng et al. 
2013), and, consequently, its immune-
modulatory function (Preusser et al. 
2015). In accordance with its proposed 
role as a PD-L1 foldase, use of selective 
inhibitors of FKBP51 isomerase activity, 
significantly impaired PD-L1 maturation, 
both constitutive and that induced  by 
treatment with IR. This result might have 
an impact in clinical practice, considering 
that combining IR and anti-PD-L1 
treatment showed to induce tumor 
regression and prevent glioblastoma 
recurrence in a mouse xenograft model 
(Carlsson and Issazadeh-Navikas 2013). I 
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also found that SAFit, in co-cultures,  
reduced apoptosis of PBMCs induced by 
glioma cells through PD-L1/PD1, which 
was expected due to PD-L1 
downregulation.  
A further objective of my thesis work was 
to investigate whether PD-L1, in addition 
to its function as a modulator of immune-
mediated antitumor response, could play 
a role as a promoter of glioblastoma 
progression sustaining cells features of 
aggressiveness, as growth rates and self-
renewal capacities. Other authors have 
demonstrated that PD-L1 sustains the 
growth of a melanoma cell subset that 
promotes tumor progression and 
metastasis formation (Zheng et al. 2017). 
To address the pro-tumoral role of PD-L1 
I availed myself of the collaboration of 
professor Rogister research group to 
work on their  mouse model of 
glioblastoma (Kroonen et al. 2011).  
Glioblastoma cells from SVZ expressed 
higher levels of PD-L1 on plasma 
membrane compared with the TM. 
Because immunoblot showed that 
glycosylated PD-L1 was increased while 
the transcript levels did not, I 
hypothesized that a post-transcriptiona l 
mechanism of PD-L1 expression 
regulated the diverse PD-L1 expression 
in SVZ and TM glioma cells. Since PI3K-
AKT-S6K1 pathway regulates the 
synthesis of PD-L1 (Parsa et al. 2007), I 
measured the phosphorylated levels of 
AKT and S6K1 that resulted in increase 
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in cells from SVZ compared with cells 
from TM. Moreover, downmodulation of 
FKBP51s by gene silencing or its 
selective chemical inhibition with SAFit2 
decreased PD-L1 expression. I found 
that, in SVZ and less in TM, FKBP51s 
co-localized with the ER. Moreover, I 
found that FKBP51s expression was less 
stable in cells from SVZ than cells from 
TM as described for ER-associated 
proteins (Khaminets et al. 2015). By 
spheroid formation assay, I found that 
modulating the expression of PD-L1 and 
FKBP51s in cells from TM and SVZ, I 
was able to decrease the capacity of the 
cell lines to form floating spheres. I 
obtained a similar result by treatment 
with SAFit2. Moreover, I found that daily 
treatment with SAFit2 decreased Ki67 
expression and the growth rate of 
glioblastoma cells from both TM and 
SVZ. Using the mouse model of 
glioblastoma I could confirm that 
treatment with SAFit2 influenced the 
tumor growth and the expression of 
vimentin, a marker of tumor 
aggressiveness, which resulted impaired 
by the daily intraperitoneal injection of 
SAFit2. As shown in Figure 13, 
collectively, these findings provide 
elements in support of a role for 1) the 
cochaperone FKBP51s in regulation of 
PD-L1 expression; 2) PD-L1 in 
supporting hallmarks of glioblastoma 
aggressiveness; 3) selective inhibitors of 
FKBP51s enzymatic function in 
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effectively impairing glioblastoma 
growth.  
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Fig 13. Proposed mechanism for 
FKBP51s-mediated regulation of PD-L1 
expression in GBM cells. 
FKBP51s interacts with PD-L1 in the ER 
and assists to protein glycosylation. 
Mature PD-L1 goes to plasma membrane 
through Golgi trafficking. PD-L1 
signaling promotes immune evasion, 
proliferation and stemnes of GBM cells. 
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6. CONCLUSIONS 
 
FKBP51s is a novel element that 
regulates PD-L1 expression in 
glioblastoma cells. The protein acts as a 
co-chaperone in the ER, promoting PD-
L1 post-translational modifications, 
occurring during protein maturation and 
controlling the correct expression of the 
protein on the plasma membrane. 
FKBP51s also promotes PD-L1 
expression induced by the treatment of 
glioblastoma with ionizing radiation. The 
spliced FKBP51 is widely expressed in 
sample tissues of glioblastomas, along 
with PD-L1. PD-L1 has a role in 
sustaining self-renewal and growth 
capacities of glioblastoma cells, which is 
particularly appreciable in a highly 
tumorigenic glioblastoma cell subset 
involved in tumor recurrence. In vitro 
inhibition of FKBP51s, either by 
silencing or chemical agent, results in 
PD-L1 downmodulation in glioblastoma 
cell lines and a decrease in the 
glioblastoma capacity to convey an 
inhibitory signal to the immune system. 
Finally, FKBP51s inhibition impairs the 
intrinsic capacity of the tumor to develop 
and grow, in vitro and in vivo. 
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